$JNJ

Joaquin Duato

Johnson & Johnson

Chairman & CEO • Since 2022 • Health Care

Also profiled in: S&P 500

📊 CEO Reputation Score

FY2025 vs FY2024 · Source: SEC EDGAR filings

61/100

Blend of this company's year-over-year free-cash-flow and profit improvement, each ranked as a percentile against every scored company in the three indexes.

Free cash flow: $19.8B → $19.7B (−0.7% YoY) — fiscal 2025 vs fiscal 2024
Profit (net income): $14.1B → $26.8B (+90.6% YoY) — fiscal 2025 vs fiscal 2024

How this score works · Dow Jones reputation leaderboard

Overview

Joaquin Duato is the chairman & ceo of Johnson & Johnson since 2022. Johnson & Johnson is a Health Care company, and one of the 30 companies in the Dow Jones — every one of which is profiled on this site.

Leadership

Joaquin holds the chief executive role at Johnson & Johnson with the title Chairman & CEO — in post since 2022. This page is the concise leadership record for Johnson & Johnson in the Dow Jones CEO index; the site's fully researched long-form profiles (career timelines, education, achievements, setbacks, philosophy and sourced quotes) currently cover the index's ten largest companies, and this entry will be expanded in the same format.

At a Glance

Sector: Health Care
Ticker: $JNJ
CEO since: 2022
Index: Dow Jones (#17 of 30)